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Idiopathic pulmonary fibrosis (IPF) is aprogressive fibrotic lung
diseasewith highmortality. Active TGF1 is considered central to
the pathogenesis of IPF. Amajormechanism of TGF1 activation
in the lung involves the epithelially restricted v6 integrin.
Expression of the v6 integrin is dramatically increased in IPF.
How v6 integrin expression is regulated in the pulmonary epi-
thelium is unknown. Here we identify a region in the 6 subunit
gene (ITGB6)promoteracting tomarkedly repressbasalgene tran-
scription, which responds to both the Ets domain-containing pro-
tein Elk1 (Elk1) and the glucocorticoid receptor (GR). Both Elk1
andGRcan regulatev6 integrin expression in vitro.Wedemon-
strateElk1binding to the ITGB6promoterbasally and thatmanip-
ulation of Elk1 or Elk1 binding alters ITGB6 promoter activity,
gene transcription, and v6 integrin expression. Crucially, we
find that loss of Elk1 causes enhanced Itgb6 expression and exag-
gerated lung fibrosis in an in vivomodel of fibrosis,whereas theGR
agonist dexamethasone inhibits Itgb6 expression. Moreover, Elk1
dysregulation is present in epithelium from patients with IPF.
Thesedatarevealanovel role forElk1regulating ITGB6expression
and highlight how dysregulation of Elk1 can contribute to human
disease.
The prognosis of idiopathic pulmonary fibrosis (IPF)2
patients is poor, with 5-year survival rates worse than most
cancers (1), and the incidence is rapidly increasing (2). IPF is
characterized by excessive matrix deposition within the lung
interstitium, leading to deteriorating pulmonary function and,
ultimately, death. IPF pathogenesis is poorly understood; how-
ever, the current paradigm suggests that recurrent epithelial
injury and failing repair promote expansion and trans-differen-
tiation of myofibroblasts within the interstitium (3). An
improved understanding of the mechanisms driving fibrogen-
esis is critical for the development of urgently needed new ther-
apeutic agents.
TGF1 is a key cytokine implicated in the development of
fibrosis (4). It has profound effects on both epithelial cells and
fibroblasts, two of the key effector cells in fibrogenesis, andmedi-
ates many of the characteristic pathologic features of fibrosis,
including epithelial cell apoptosis, myofibroblast trans-differenti-
ation, and subsequent collagen production (5, 6). For TGF1 to
exert any biological effect, itmust first be activated, and activation
by thev6 integrin is an important feature in experimentalmod-
els of fibrosis in multiple organ systems (7–12).
Fundamentally, high levels ofv6 integrins have been dem-
onstrated in lung tissue from patients with pulmonary fibrosis
(9, 13) and are associatedwith aworse prognosis (14). Similarly,
levels of 6 subunit mRNA (ITGB6) correlate with increasing
severity of fibrosis in the liver (15). The molecular mechanisms
regulating the expression levels ofv6 integrins are, therefore,
likely to be critical for ensuring normal repair in response to
injury rather than pathological fibrosis. Such mechanisms,
however, have not been investigated in detail.
It has been shown previously that TGF1 increases ITGB6
levels and elevates expression of v6 integrins by guinea pig
airway epithelial cells in vitro (16), and a positive feedback loop
of v6-mediated TGF1 activation promoting enhanced
integrin expression in the lung has been proposed (17). It is
possible that TGF1-independent pathways may also contrib-
ute to ITGB6 regulation. For example a potential role for ets-1
during increased transcription of the ITGB6 gene has been
suggested (18), and overexpression of active Stat3 leads to
increased ITGB6 expression in carcinogenesis (19). However,
whether these mechanisms are involved in up-regulation of
ITGB6 in pulmonary fibrosis is unknown.
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This study aimed to investigate the molecular mechanisms
driving ITGB6 expression in lung epithelial cells and investigate
the importance of these pathways in fibrogenesis.We identified
a novel region of the ITGB6 promoter responsible for repress-
ing transcription and demonstrate that Elk1, as well as the glu-
cocorticoid receptor (GR), can act to repress the ITGB6 gene.
We demonstrate that Elk1 deficiency in vivo enhances Itgb6
expression and exacerbates bleomycin-induced fibrosis in
mice, whereas the GR agonist dexamethasone represses Itgb6
expression. Finally, we show that lung tissue from pulmonary
fibrosis patients displays reduced Elk1 expression associated
with reduced Elk1 binding to the ITGB6 promoter. These data
highlight a novel and crucial function of the transcription factor
Elk1 in modulating v6 expression in the lung.
Experimental Procedures
Cell Lines and Reagents—Immortalized human bronchial
epithelial cells (iHBECs, a gift from Prof. Jerry Shay, University
of Texas) or small airway epithelial cells (SAECs, Lonza) were
used for many in vitro experiments. The iHBEC immortalized
cell line was selected over primary alveolar epithelial cells for
the majority of in vitro studies because of the technical advan-
tages in performing molecular mechanistic studies such
as transfections and ChIP in these cells. iHBECs retain their
ability to differentiate into basal, mucin-producing, and ciliated
epithelial cells (20). Furthermore, iHBECs are one of the only
immortalized or transformed lung epithelial cell lines that
retain theirv6 integrin expression in vitro. iHBECswere cul-
tured in keratinocyte serum-free medium (Lonza) containing
bovine pituitary extract (Lonza), epidermal growth factor
(Lonza), G418 (Sigma-Aldrich), puromycin (Sigma-Aldrich),
and penicillin and streptomycin (both from Sigma-Aldrich).
Primary SAECswere used to confirm some findings obtained
in iHBECs. They were cultured in small airway growthmedium
(Lonza) containing the supplied supplements. All cells were
growth-arrested in supplement-free medium for 24 h prior to
the start of experiments, except in the case of transfection
experiments. To assess binding of endogenous Elk1 to exoge-
nous ITGB6 promoter constructs, we used the adenosquamous
carcinoma cell line H647 after determining that these cells
exhibit a high expression level of endogenous Elk1. H647 cells
were cultured in RPMImedium (Sigma-Aldrich)with 10%FCS,
L-glutamine, penicillin, and streptomycin.
Elk1 and GAPDH antibodies for Western blotting were sup-
plied by Cell Signaling Technology. All siRNA constructs and
the associated reagents were provided by Santa Cruz Biotech-
nology. Formaldehyde, glycine, dexamethasone, and progester-
one were supplied by Sigma-Aldrich. Phycoerythrin-labeled or
FITC-labeled secondary antibodies for flow cytometry, TRIzol
reagent, zysorbin, the TA cloning kit, and T4 ligase were sup-
plied by Invitrogen. All reagents required for the synthesis of
cDNA from RNA, including Moloney murine virus reverse
transcriptase, and all plasmids not provided by Addgene or a
collaborator plus Transfast reagent were provided by Promega.
Kapa Taq polymerase for use in QPCR reactions was supplied
by Kapa Biosystems. All ChIP antibodies were obtained from
Abcam.
Flow Cytometry—Flow cytometry was used to assess v6
cell surface expression as described previously (13). Briefly,
iHBECs were labeled with 10 g of anti-v6 antibody (clone
6.3G9) (21) and a PE-labeled anti-mouse secondary antibody. A
secondary antibody-only negative control was performed. Flu-
orescence was assessed using a BD FACSDIVA flow cytometer.
Quantitative PCR—Gene expression of both human and
murine genes was measured using an MxPro3000 instrument
(Stratagene) andKapaTaq using the following primer sequenc-
es: human ITGB6, 5-AAACGGGAACCAATCCTCTGT-3
(sense)and5-GCTTCTCCCTGTGCTTGTAGGT-3 (antisense);
human 2-microglobulin (B2M), 5-AATCCAAATGCGGCA-
TCT-3 (sense) and 5-GAGTATGCCTGCCGTGTG-3 (anti-
sense); human ELK1, 5-CCACCTTCACCATCCAGTCT-3
(sense) and 5-TCTTCCGATTTCAGGTTTGG-3 (antisense);
and murine Itgb6, 5-TCTGAGGATGGAGTGCTGTG-3
(sense) and 5-GGCACCAATGGCTTTACACT-3 (anti-
sense). All QPCR reactions were performed at an annealing
temperature of 60 °C. Amplification of a single DNA product
was confirmed by melting curve analysis. Data were
expressed as relative expression using the Ct equation.
Generation of the ITGB6 Promoter Deletion Mutant Series—
The 1.1-kb insert was excised from pGL2-ITGB6 (18) and
ligated into the pGL3 vector (Promega) usingT4 ligase and then
sequenced to verify the presence of the insert. Progressively
truncated forms of the reporter (Fig. 1A) were amplified by PCR
and TA-cloned with a commercially available kit (Invitrogen).
The purified inserts were then ligated into the pGL3 vector
using T4 ligase (Invitrogen) and sequenced to confirm the pres-
ence of the correct insert.
Reporter Construct Transfections—Transient transfections
were performed using Transfast (Promega) transfection re-
agent using 0.75 g of reporter plasmid DNA with 7.5 ng of
Renilla luciferase DNA at a 1:2 DNA:Transfast ratio. Briefly,
cells were seeded at 2 105 cells/ml and then cultured for 8 h in
supplemented keratinocyte serum-free medium prior to trans-
fection overnight in unsupplemented keratinocyte serum-free
medium. The following day, cells were stimulated as required
for the experiment. To assess the binding of endogenous Elk1 to
ITGB6 reporter constructs, 0.75 g of reporter plasmid DNA
was transfected in toH647 cells at a 1:2DNA:Transfast ratio for
24 h.
siRNA Transfections—siRNA directed toward Elk1, GR, or a
control siRNA were transfected into iHBECs using the siRNA
transfection reagents and protocol provided by Santa Cruz Bio-
technology. 40 pmol of siRNA was used per well of cells in a
24-well plate. Cells were transfected for 24 h prior to the start of
an experiment to allow sufficient knockdown of target protein.
Site-directed Mutagenesis (SDM)—Site-directed mutagene-
sis was performed using the QuikChange II site-directed
mutagenesis kit (Agilent) according to the instructions of the
manufacturer. The Elk1 binding sites located at772 (reverse
strand) and 752 were mutated from GGAA to AAGA using
the following primers: sense, 5-CCCCCAGGGTGTTCTTC-
AAAGAGGTGTTTTGAGATTTGTAGAGTC-3; antisense,
5-GACTCTACAAATCTCAAAACACCTCTTTGAAGAA-
CACCCTGGGGG-3. All constructs were sequenced prior to
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use in experiments to confirm the presence of the correct
mutation.
Chromatin Immunoprecipitation—ChIP allowed the binding
of proteins to the ITGB6 promoter to be determined. The
ChIP-IT Express kit (Active Motif) was used to assess binding
in cultured cells as described previously for airway smooth
muscle cells (22). Briefly, cells were fixedwith 1% formaldehyde
for 5 min and lysed prior to shearing of the cellular chromatin
by sonication using an Epishear sonicator (ActiveMotif). 25g
of total chromatin was immunoprecipitated with 10 g of anti-
body and protein G magnetic beads. ChIP QPCR data were
normalized to input chromatin (i.e. the amount of total chro-
matin present in the immunoprecipitation sample) and then
expressed as relative binding comparedwith the control sample
using the Ct equation. ChIP QPCR primer sequences were
as follows, using an annealing temperature of 60 °C: ITGB6 pro-
moter 934 to 753, 5-CATGCTTACCCAGGAATGCT-3
(sense) and 5-ACACCCTGGGGGAAAAATAC-3 (anti-
sense); ITGB6 promoter 1604 to 1497, 5-ACTGCCCTC-
CAGCCTAGAA-3 (sense) and 5-TTGACAGAAACTAAA-
TGCCCAA-3 (antisense).
ChIP on human lung tissue was performed by first creating a
single-cell suspension by passing the tissue through a 100-m
cell strainer. The cellular chromatin was then cross-linked in
1% formaldehyde for 5 min. The cross-linking was reversed
with glycine, the cells were lysed in 10% SDS, and then the
chromatin was sheared by sonication using an Epishear sonica-
tor (Active Motif). 100 g of total tissue chromatin was sub-
jected to immunoprecipitation with 10 g of Elk1 antibody
overnight. Antibody-bound DNA was extracted using
Zysorbin.
ChIP was employed to assess binding of endogenous Elk1
protein to exogenous ITGB6 promoter plasmid constructs.
H647 cells were used, which we found to express high levels of
endogenous Elk1 (data not shown). Following transfection and
expression of exogenous constructs, the cells were formalde-
hyde-fixed and processed as stated above for other cultured
cells. QPCR of the resulting immunoprecipitated DNA was
performed using primers directed against the luciferase
sequence of the pGL3 plasmid to assess Elk1 binding only to
exogenous DNA, not endogenous DNA (sense, 5-GCTTTTA-
CAGATGCACATATC-3; antisense, 5-CCATACTGTTGA-
GCAATTCACG-3). Relative binding was normalized to the
input chromatin luciferase critical threshold signal (i.e. the
amount of luciferase plasmid DNA present) to ensure that dif-
ferences in transfection efficiency between the constructs did
not affect detection of Elk1 binding levels. Data were expressed
as relative binding to the non-mutated ITGB6 promoter con-
struct using the Ct equation.
Western Blotting—Human lung tissue was homogenized
using a mechanical tissue tearer in ice-cold lysis buffer (20 mM
Tris-HCl, 137 mM NaCl, 1% Triton X-100, 2 mM EDTA, and
10% glycerol, all supplied by Sigma-Aldrich) supplemented
with protease and phosphatase inhibitors (CompleteMini pro-
tease inhibitor tablet and Phos-stop inhibitor tablets, Roche).
Expression of Elk1, GR, and GAPDH proteins wasmeasured by
Western blotting as described previously for Smad2/3 (23).
Briefly, protein concentrations in each samplewere determined
using BCA (Pierce) according to the instructions of the manu-
facturer and using increasing concentrations of bovine serum
albumin as a standard curve. 100g of total protein was loaded
into each lane of an SDS-PAGE gel, and a current of 150 V was
applied for 60 min. The gel was transferred onto a polyvi-
nylidene membrane, blocked with 5% nonfat milk, and then
probed with the following antibodies overnight: rabbit anti-
Elk1 (Cell Signaling Technology, 9182) at 1:1000 dilution, rab-
bit anti-GR (Cell Signaling Technology, 3660) at 1:1000 dilu-
tion, and goat anti-GAPDH (V-18, Santa Cruz Biotechnology)
at 100 ng/ml. All horseradish peroxidase-conjugated secondary
antibodies were used at 333 g/ml and were purchased from
Dako. Western blotting films were scanned, and the band den-
sity was calculated by inverting the image andmeasuring mean
gray pixels using Adobe Photoshop CS5 Extended (32-bit, ver-
sion 12.1).
In Vivo Bleomycin Model of Pulmonary Fibrosis—Male
Elk1/0 (24) and wild-type mice (aged 5–7 weeks) were treated
with either 0 or 60 IU of bleomycin sulfate in 50 l of saline via
the oropharyngeal route under isoflurane anesthesia (2.5%, 2
liters/min flow of oxygen). All tissue was collected 28 days after
bleomycin treatment. The lungs were either excised and snap-
frozen at80 °C for mRNA and hydroxyproline assessment or
insufflated with formalin at constant gravitational pressure (20
cm H2O) and then paraffin wax-embedded for histology and
immunohistochemistry.
To assess the role of GR in regulating Itgb6 mRNA in vivo,
male 6-week-old C57/black6/J mice were treated with either 60
of IU bleomycin in 50 l of saline or saline only as a control via
the oropharyngeal route under isoflurane anesthesia (2.5%, 2
liters/min). All animals also received daily treatment with
either 1 mg/kg dexamethasone (100-l volume) or PBS only as
a control via intraperitoneal injection. After 14 days, the lungs
were removed and snap-frozen at80 °C for subsequent RNA
analysis.
Immunohistochemistry—5-m-thick sections of paraffin
wax-embedded lung tissue of murine and human origin was
subjected to immunohistochemistry to evaluate expression lev-
els of v6 integrin as described previously (13). An antibody
directed against murine v6 (clone ch2.A1) and an antibody
directed against human v6 (clone 6.3G9) were provided by
Biogen Idec. Murine tissue from the bleomycin model of pul-
monary fibrosis was also subjected to immunohistochemistry
to detect levels of pSmad2.Tissue sectionswere boiled in 10mM
citrate buffer to retrieve endogenous antigens and then exposed
to anti-pSmad2 antibody (1:500 dilution, Cell Signaling Tech-
nology) overnight. Staining was visualized with 3,3-diamino-
benzidine as for v6.
Human lung tissue from four fibrotic and four non-fi-
brotic donors was subjected to immunohistochemistry to
detect levels of either v6 (see above for v6) or Elk1. For
Elk1, tissue was dewaxed and rehydrated and then boiled in
10 mM citrate buffer. Following blocking in 5% donkey
serum, the sections were incubated overnight with either
Elk1 antibody (1.1 g/ml, Abcam clone E277). Staining was
visualized using 3,3-diaminobenzidine. All staining was
visualized using a Nikon 90i light microscope and NIS Ele-
ments image acquisition software.
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Quantification of pSmad2-positive Nuclei—Quantifica-
tion was performed using a Nikon Eclipse 90i microscope
andNikonNIS Elements software. Five random fields of view
at 20 magnification were observed per tissue section. All
brown nuclei present in the field of view were counted.
Masson Trichrome Histological Staining—5-m-thick histo-
logical sections of lung tissue were dewaxed and rehydrated
using xylene and decreasing concentrations of ethanol. The tis-
sues were incubated overnight at room temperature in Bouin
solution. The lung tissue was then subjected to consecutive his-
tological staining in Weigert solution (5 min), Biebrich scarlet
acid fuchsin (5 min), phosphomolybolic acid/phototungstic
acid (7 min), analine blue (5 min), and 1% acetic acid (1 min).
The sections were then dehydrated and imaged using a Nikon
Eclipse 90i microscope.
Isolation of mRNA from Lung Tissue—Human and murine
lung tissue was ground to powder in liquid nitrogen using a
pestle andmortar. Frozen lung tissue was then added to TRIzol
reagent (1 ml TRIzol/0.5 g of tissue) and incubated on ice for 5
min prior to the addition of chloroform (200 l/ml TRIzol).
The samples were centrifuged at 11,000 g for 20 min to allow
phase separation, and then the aqueous layer was transferred to
a new tube. RNA was precipitated by addition of 500 l of
isopropyl alcohol and 1 l of glycogen and centrifuged. The
RNA was washed in 75% ethanol prior to being resuspended in
nuclease-free water.
Hydroxyproline Assay—Hydroxyproline levels in murine
lung tissue were measured as described previously (25). Briefly,
lung tissue was hydrolyzed in 6 N HCl at 100 °C overnight, and
the hydrosylate was resuspended in water. 1.4% chloramine T
in 10% isopropanol and 0.5 M sodium acetate were added for 20
min, followed by Erlich solution for 15 min at 65 °C. Absorb-
ance was measured at 550 nm.
Human Tissue and Ethical Approval—Lung tissue from pul-
monary fibrosis patients (PF) was obtained either post-mortem
or from lung transplant patients following informed written
consent and ethical review (ethical approval numbers: Notting-
ham Respiratory Research Unit, 08/H0407/1; Papworth Hospi-
tal Research Tissue Bank (REC), 08/H0304/56; University of
California San Francisco Institutional Review Board, 10-00198;
South East Scotland Scottish Academic Health Sciences Col-
laboration Bioresource, 06/S1101/41). In all cases, the patho-
logical diagnosis was usual interstitial pneumonia, and the clin-
ical diagnosis of IPF was made on the basis of American
Thoracic Society/ European Respiratory Society consensus cri-
teria (26). Non-fibrotic human lung tissue was obtained from
non-cancerous tissue removed during surgery or from donor
lungs unsuitable for transplant. All experiments were per-
formed in accordance with the World Medical Association
Declaration of Helsinki.
Animal studies using bleomycin were approved by the Uni-
versity of Nottingham Ethical Review Committee and per-
formed under Home Office Project and Personal License
authority within the Animals (Scientific) Procedures Act of
1986. Animals received free access to food and water at all
times.
Statistics—All cell-based experiments were repeated three
times and expressed as mean data from the three independent
experiments. Statistical significance was determined by either t
test when comparing two data sets or analysis of variance for
comparing multiple datasets. Data from experiments compar-
FIGURE 1. The ITGB6 gene promoter contains a large repressor region. A,
schematic demonstrating the series of deletion mutants of the full-length
pGL3-ITGB6 promoter luciferase reporter construct. TSS, transcription start
site.B, iHBECswere transfectedwith the either emptypGL3 vector, full-length
ITGB6 promoter reporter, or a series of ITGB6 promoter deletion mutants.
After 4 h, luciferase activity was measured to determine promoter activity.
Data are expressed as mean  S.E. relative to the firefly/Renilla ratio from
three independent experiments. *, p 0.05. C, in silico analysis revealed the
presence of several transcription factor binding sites between 818 and
731 from the transcription start site. This schematic shows these transcrip-
tion factor binding sites.
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ing PF and control non-fibrotic (NF) human tissues were not
normally distributed. Therefore, a non-parametric Mann-
Whitney U test was used to determine significance. p  0.05
was accepted as significant in all cases.
Results
The ITGB6 Gene Promoter Contains a Putative Repressor
Region—To investigate the presence of transcriptional regula-
tory regions within the ITGB6 gene promoter, we created a
series of truncated ITGB6 promoter luciferase reporter con-
structs from the 1.1-kb ITGB6 promoter reporter used by oth-
ers (18) (Fig. 1A).With progressively decreasing size, transcrip-
tion factor binding sites are lost from the reporter constructs.
This series of reporter constructs was transfected into iHBECs,
and luciferase activity was measured after 4 h. Loss of the most
distal regions of the ITGB6 promoter led to dramatic increases
in basal promoter activity (Fig. 1B). The increase in basal pro-
moter activity was greatest when the 818 to 731 region of
the promoter was absent, suggesting that this region contains
important negative regulatory elements. In silico analysis using
Transcription Element Search Software (University of Pennsyl-
vania) indicated binding sites for several transcription factors
within the region 818 to 731. A schematic showing this
putative repressor region is shown in Fig. 1C.
Elk1 Represses ITGB6 and v6 Expression in Vitro—Previ-
ous studies have suggested a role of ets family transcription
factors in regulating the ITGB6 promoter (18). Therefore, we
initially investigated the role of Elk1 in ITGB6 regulation. Using
ChIP, we demonstrated that Elk1 bound to the putative repres-
sor region of the ITGB6 promoter in lung epithelial cells under
basal conditions, but binding was not detected at a control
region of the promoter upstream of the repressor region (Fig.
2A). SDM of Elk1 binding motifs was utilized to investigate the
effect of interrupting binding of Elk1 to the ITGB6 promoter,
which contains two Elk1 binding sites within the putative
repressor region (at772 and752). ChIP was used to assess
binding of endogenous Elk1 protein to the exogenous mutated
and non-mutated promoter constructs. Binding of endogenous
Elk1 to the exogenous, unmutated pGL3-ITGB6 construct was
detected; however, binding above an IgG control was not
detected when either Elk1 site was mutated individually or
when both sites were mutated simultaneously (Fig. 2B).
Following confirmation that Elk1 was unable to bind to the
ITGB6 promoter when the binding sites were mutated, the
effect of mutating the Elk1 binding sites on promoter activity
was assessed.Mutation of the Elk1 binding site at772 resulted
in a small but significant rise in ITGB6 promoter activity,
whereasmutation of the binding site at752 had no significant
effect (Fig. 2C). However, mutation of both binding sites
together resulted in a larger increase in ITGB6 promoter activ-
ity, which was greater than the increase observed when the
772 site was mutated alone (Fig. 2C).
To determine whether Elk1 repressed ITGB6mRNA expres-
sion, we utilized an Elk1 siRNA that reduced Elk1 protein and
mRNA expression compared with control siRNA (Fig. 2,D and
E). Transfection of Elk1 siRNA increased basal ITGB6 pro-
moter activity (Fig. 2F), suggesting a loss of basal transcriptional
repression. Supporting these molecular studies, we demon-
strated that Elk1 siRNAalso led to a significant increase inv6
cell surface protein levels 2 days following transfection (Fig. 2,G
andH). These data demonstrate that Elk1 regulates in vitro lung
epithelial cell v6 integrin expression.
Glucocorticoid Receptor, but Not Progesterone Receptor,
Represses v6 Expression—The repressor region identified
contains a number of putative transcription factor binding sites
(Fig. 1C), and the degree of repression mediated by Elk1 was
considerably lower than what was observed by deletion of the
complete repressor region. We therefore hypothesized that
other transcription factors may be contributing to ITGB6
repression. The receptors for glucocorticoids and progesterone
had been identified in the repressor region; therefore, we inves-
tigated the effect of these hormones on ITGB6 expression. Dex-
amethasone had no effect on the basal activity of the full-length
ITGB6 promoter after 4 h but inhibited TGF1-induced
increases in ITGB6 promoter activity in iHBECs (Fig. 3A).
However, treatment of SAECs with dexamethasone for 3 days
resulted in a reduction in cell surface expression of v6 integ-
rins (Fig. 3,B andC). Additionally, a siRNA targetingGR,which
reduced GR protein expression (Fig. 3D), caused a small but
consistent increase inv6 expression over 2 days (Fig. 3,E and
F). Similar to dexamethasone, progesterone had no significant
effect on basal ITGB6 promoter activity but abrogated TGF1-
induced increases in promoter activity (Fig. 3G). However, pro-
gesterone had no significant effect on ITGB6mRNAexpression
over 24 h (Fig. 3H) or any effect on v6 cell surface expression
in SAECs over 3 days (Fig. 3I). These data suggested that,
although glucocorticoidsmay affect ITGB6 expression, proges-
terone was unlikely to be involved in v6 regulation.
Having identified two transcription factors (Elk1 and GR)
capable of binding the putative repressor region and repressing
ITGB6 and v6, we sought to determine whether they co-reg-
FIGURE 2.v6 is repressedby Elk1binding to the ITGB6promoter at772 and752.A, basal binding of Elk1 to the repressor region of the endogenous
ITGB6promoter (934 to753) and a control region (1604 to1497)was assessedbyChIP in iHBECs. Binding of Elk1 above IgGbinding levelswas detected
at the repressor region but not at the control region. Data are expressed asmean S.E. relative binding (relative to IgG) from three independent experiments.
B, SDM of Elk1 sites located at either772,752, or both was performed. H647 cells were transfected with either non-mutated pGL3-ITGB6 reporter or either
of the mutated constructs for 24 h. ChIP was performed for endogenous Elk1. Relative binding above IgG was calculated relative to the full-length, non-
mutated promoter construct. Shown is mean relative binding S.E. from three independent experiments. C, SDM of Elk1 sites located at either772,752,
or bothwasperformed. iHBECswere transfectedwith these constructs, and luciferase activitywasmeasured. Data are expressed asmean relative firefly/Renilla
ratio S.E. from three independent experiments. *, p 0.05. D, iHBECs were transfected with Elk1 or control siRNA, and Elk1 expression was measured by
Western blotting. The figure is representative of three independent experiments. The ratio of Elk1:GAPDH as calculated by densitometry is shownbeneath the
bands. E, iHBECs were transfected with Elk1 or control siRNA, and ELK1 mRNA was assessed. Data are expressed as mean ELK1 expression  S.E. from two
independent experiments. *,p0.05. F, iHBECswere cotransfectedwith Elk1 or control siRNAwith the full-length ITGB6promoter reporter. Data are expressed
asmean relative firefly/Renilla S.E. from three independent experiments. *, p 0.05.G, iHBECswere transfectedwith either control siRNA or Elk1 siRNA, and
v6expressionwasassessedafter 2days.Gray line, negative control (-ve);black solid line, control siRNA;dotted line, Elk1 siRNA. Thehistogram is representative
of three independent experiments. H, amalgamated data from the experiments shown in G expressed as -fold change MFI. *, p 0.05.
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ulatedv6 expression. First, we utilized a combination of dex-
amethasone treatment to activate GR and Elk1 siRNA and
assessed the effect on v6 expression. Confirming the data
shown in Fig. 2G, transfection of iHBECs with Elk1 siRNA
caused a modest but significant increase in v6 expression
(Fig. 4A). However, activation of the GR with dexamethasone
for 2 days did not affect v6 levels in the presence of either
control or Elk1 siRNA (Fig. 4A).We next investigated the effect
of dexamethasone treatment on TGF-induced increases in
v6 expression. Despite showing a trend toward reducing
FIGURE 3.Theglucocorticoid receptor, but not theprogesterone receptor, repressesv6.A, iHBECs transfectedwith the ITGB6promoter reporter (black
columns) or an empty vector control (white columns) were stimulated with 2 ng/ml TGF1, 10 M dexamethasone (Dex), or TGF1 and dexamethasone
together. Data are expressed as mean relative firefly/Renilla ratio  S.E. from three independent experiments. *, p  0.05. B, SAECs were stimulated with
dexamethasone for 3 days, and v6 was assessed. Gray line, negative control; solid line, 0 M; dotted line, 10 M. The histogram is representative of three
independent experiments. C, the data shown in B expressed as a bar chart. Shown are amalgamated data from three independent experiments expressed as
-fold changeMFI. **, p 0.01.D, iHBECswere transfectedwith control or GR siRNA, andGR protein expressionwas determined byWestern blotting to confirm
GR knockdown. The figure is representative of three independent experiments. The ratio of GR:GAPDH as calculated by densitometry is shown beneath the
bands. E, iHBECs were transfectedwith control or GR siRNA, andv6was assessed after 2 days.Gray line, negative control (-ve); black solid line, control siRNA;
black dotted line, GR siRNA. The histogram is representative of three independent experiments. F, the data shown in E expressed as a bar chart. Shown are
amalgamateddata from three independent experiments expressed as -fold changeMFI. **,p 0.01.G, iHBECswere transfectedwith either an ITGB6promoter
reporter (black columns) or an empty vector control (white columns) and stimulated with TGF1 (2 ng/ml), progesterone (Prog, 10 M), or TGF1 and proges-
terone in combination. Data are expressed as mean relative firefly/Renilla ratio  S.E. from three independent experiments. **, p  0.01. H, iHBECs were
stimulated with 10 M progesterone, and ITGB6mRNAwas measured by QPCR over 24 h. Data are expressed as mean -fold change relative to 0 h S.E. from
three independent experiments. I, SAECswere stimulatedwith 10M progesterone, andv6was assessed.Gray line, negative control; solid line, 0M; dotted
line, 10 M progesterone. The histogram is representative of three independent experiments.
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TGF-induced v6 expression, dexamethasone did not have
a statistically significant effect on TGF-induced increases
in v6 expression in iHBECs after 2 days (Fig. 4B). Finally,
iHBECs were transfected with Elk1 or GR siRNAs or both
siRNAs in combination, and v6 expression was measured
in unstimulated and TGF-stimulated cells. Both Elk1 and
GR siRNA increased basal v6 expression, as shown previ-
ously, although transfection of both siRNAs did not act syn-
ergistically to further enhance v6 cell surface levels (Fig.
4C). Transfection with Elk1 and GR siRNA had a similar
effect on TGF-stimulated cells, although the increase was
not statistically significant compared with TGF alone (Fig.
4C).
Loss of Elk1 in Vivo Results in an Exaggerated Response to
Bleomycin-induced Lung Fibrosis—Although the in vitro data
suggested that Elk1 was unlikely to mediate complete repres-
sion of the ITGB6 promoter, we hypothesized that even mod-
erate effects on epithelial v6 integrin expression were likely
to be important in response to injury. Therefore, to determine
whether global loss of Elk1 was sufficient to increase Itgb6
expression in vivo and exacerbate fibrotic responses, we
employed the bleomycin model of lung fibrosis. Elk1/0 male
mice and wild-type littermate controls (Elk1/0) were instilled
with saline or 60 IU of bleomycin. Lungswere harvested 28 days
following bleomycin instillation, and then lung fibrosis and
Itgb6 mRNA levels were measured. Bleomycin increased the
levels of Itgb6 mRNA in homogenates of Elk1/0 and Elk1/0
whole lung tissues. However, there were significantly greater
levels of Itgb6 mRNA in the lungs of Elk1/0 animals treated
with bleomycin (Fig. 5A).
Lung fibrosis was quantified by measuring levels of hydroxy-
proline in lung tissue and by assessing histology using Masson
trichrome stain. Bleomycin treatment increased lung hydroxy-
proline levels in both Elk1/0 and Elk1/0 animals. However,
lungs from bleomycin-treated Elk1/0 mice contained signifi-
cantly higher levels of hydroxyproline compared with bleomy-
cin-treated Elk1/0 animals (Fig. 5B). To confirm that deposi-
tion of collagen in the lungs in response to bleomycin was
greater in Elk1/0 animals compared with control animals, his-
tological sections of lung tissue were stained with Masson
trichrome. Low-power, stitched images of entire lung lobes
demonstrate the patchy nature of lung fibrosis following bleo-
mycin-induced lung injury but show that the areas of fibrosis
were considerably larger in the Elk1/0 animals compared with
control animals (Fig. 5, C and D), and this was confirmed in
high-power images (Fig. 5E, i–iv). Lung tissue from these ani-
mals was also stained by immunohistochemistry for v6
integrins. There was no evidence of v6 protein expression in
lungs of injured mice (data not shown), consistent with previ-
ous reports (25). Although expression of v6 integrin was evi-
dent in areas of lung damage in both Elk1/0 and Elk1/0 ani-
mals, expression was markedly increased in Elk1/0 compared
withwild-type control animals (Fig. 5E, v and vii). Furthermore,
Elk1/0 animals demonstrated a trend toward increased
pSmad2 staining compared with Elk1/0 animals (Fig. 5, E, vi
and viii, and F), consistent with reduced Elk1 expression, lead-
ing to enhanced expression of TGF-activating integrins.
Taken together, these data support the hypothesis that Elk1 is
capable of suppressing Itgb6 mRNA and v6 expression in
vivo and ultimately limit the fibrotic response to injury in vivo.
Having identified that GR could also repress ITGB6 in vitro,
we evaluated its effect in vivo. Animals were treated with bleo-
mycin to induce lung injury and Itgb6 expression or with saline
and received daily intraperitoneal injections of either dexam-
ethasone or a PBS control. Itgb6mRNA levels were determined
FIGURE 4. Inhibiting the actions of Elk1 and GR simultaneously does not
have an additive effect on v6 repression. A, iHBECs were transfected
with Elk1 siRNA for 24 h and then stimulated with either 0 or 10 M dexam-
ethasone. v6 expression was determined after 2 days. Shown are amal-
gamated data from three independent experiments. Data are expressed as
-fold change in MFI relative to negative control (-ve). *, p  0.05. B, iHBECs
were left unstimulated or stimulated with 2 ng/ml TGF, 10 M dexametha-
sone (Dex), or both agonists in combination for 3 days. v6 expression was
determined by flow cytometry. Shown are amalgamated data from three
independent experiments. Data are expressed as -fold change in MFI. *, p
0.05. C, iHBECs were transfected with either control siRNA, Elk1 siRNA, GR
siRNA, or both siRNAs in combination for 24 h. The cells were then treated
with 0 or 2 ng/ml TGF for 2 days. v6 expression was measured by flow
cytometry. Shown are amalgamated data from three independent experi-
ments. Data are expressed as -fold change in MFI. *, p 0.05; **, p 0.01.
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in the lungs after 14 days. There was a clear trend toward
reduced Itgb6 expression in both the saline and bleomycin
groups treated with daily dexamethasone compared with the
groups treated with daily PBS (Fig. 5G), but this did not reach
statistical significance. However, when the data were analyzed
to determine any effect of dexamethasone irrespective of the
presence of lung injury, there was a significant reduction in
Itgb6 mRNA following dexamethasone treatment compared
with PBS treatment (p 	 0.01). This effect was also observed
after 21 days of treatment (data not shown). These data confirm
the in vitro observations and show that Elk1 and GR can regu-
late expression of Itgb6 in murine lung.
The Repressor of ITGB6 Transcription, Elk1, Is Reduced in
Pulmonary Fibrosis—Having identified that Elk1 is important
for repression of ITGB6 expression in the lung, we hypothe-
sized that this pathway would be dysregulated in human dis-
ease.We have previously demonstrated that ITGB6mRNA lev-
els are increased in lung tissue homogenates from lung fibrosis
patients (25), whichwe again found in this study (Fig. 6A). ChIP
analysis demonstrated that there was binding of Elk1 to the
ITGB6 promoter in non-fibrotic human lung tissue and that
there was reduced binding in samples from patients with PF
(p 	 0.05, Fig. 6B). It was clear that, in some patients with PF,
there was no detectable binding of Elk1 to the ITGB6 promoter
above IgG controls (Fig. 6B). Therefore, levels of Elk1 protein
were assessed by Western blotting in PF and NF lung tissue
samples. Elk1was expressed in all control samples tested (Fig. 6,
C and D), but the levels were lower, and in some cases unde-
tectable, in the PF tissue tested. Quantification of the Western
blotting signals by densitometry demonstrated that PF patients
had significantly less Elk1 protein than controls (Fig. 6C). The
specificity of the antibody used was confirmed by probing pro-
tein samples from both wild-type and Elk1/0 animals. Elk1
protein was detected in wild-type animals but not Elk/0 ani-
mals (Fig. 6E).
To assess expression of Elk1 protein macroscopically in
human lung tissue, serial sections of paraffin wax-embedded
lung tissue fromNF (n	 4) and PF (n	 4) donors were immu-
nostained for bothv6 and Elk1. Confirming previous reports
(13), NF donors had low levels of v6 expression within the
alveolar epithelium (Fig. 6F, i). In contrast, lung tissue from PF
donors demonstrated marked expression of v6 integrins
within the alveolar epithelium that was particularly evident
around regions of fibrosis (Fig. 6F, ii). Supporting a role for Elk1
being responsible for negative regulation of v6 integrins and
confirming that Elk1 protein expression is aberrant in fibrosis,
we found that NF donors had high levels of epithelial Elk1 pro-
tein expression, whereas PF donors had minimal expression of
Elk1 within the lung epithelium (Fig. 6F, iii and iv).
Discussion
IPF is a progressive lung disease with extremely poor survival
andno effective treatments. Activation ofTGF viav6 integ-
rins, the expression of which is limited to epithelial cells, is a
fundamental process in the pathogenesis of pulmonary fibrosis
(7, 9, 11). Interactions between lung epithelial cells and fibro-
blasts, partly through epithelial cell v6-mediated TGF acti-
vation, are now thought to be critical to the development and
progression of lung fibrosis (4). A common observation in IPF
patients and in other fibrotic disorders is the up-regulation of
v6 integrins within the epithelium (9, 12, 14, 15). Themolec-
ular mechanisms driving enhanced v6 expression, however,
have not been fully investigated. In this study, we highlighted a
region of the ITGB6 gene promoter responsible for repressing
basal gene transcription and, fundamentally, identified a novel
and important function for the transcription factor Elk1 in
fibrosis as a negative regulator of ITGB6 and v6 integrins in
epithelial cells.
Previous studies have suggested that recombinant Elk1
reduces activity of an exogenous ITGB6 promoter in the
HEK293 cell line (18). Our data are consistent with these find-
ings and demonstrate that loss of Elk1 or interruption of the
ability of Elk1 to bind to the ITGB6 promoter increases ITGB6
promoter activity in lung epithelial cells, which can, in turn,
lead to increased expression of v6 integrins in vitro. Further-
more, loss of Elk1 in vivo increased levels of Itgb6 mRNA and
collagen deposition in a bleomycin model of lung fibrosis. Elk1
is a ternary complex factor that is commonly thought of as an
activator of transcription when phosphorylated. However, it
also contains an R domain that can potently repress transcrip-
tion (27). The role of Elk1 phosphorylation has not yet been
determined on ITGB6 expression and may prove to be an
important regulatory pathway. It is possible that dynamic reg-
ulation between unphosphorylated Elk, which functions as a
transcriptional repressor, and phosphorylated Elk1, which can
FIGURE 5. Loss of Elk1 in vivo results in an exaggerated response to bleomycin-induced lung fibrosis. A, Itgb6 mRNA levels were measured in lung
homogenatesbyQPCRandwere significantly elevated inbleomycin (Bleo)-instilled Elk1/0mice (n	5mice) comparedwithbleomycin-treated Elk1/0 control
mice (n	 7 mice). *, p 0.05. B, total lung collagen, assessed by hydroxyproline levels, was significantly elevated in bleomycin-instilled Elk1/0 mice (n	 5
mice) compared with Elk1/0 controls (n	 7 mice). *, p 0.05; **, p 0.01. C, lung collagen was stained using Masson trichrome. Nikon NIS Elements was
utilized to imageanentire lung lobe froman Elk/0animal todemonstrate thedepositionof collagenacross the lobe. Shown is a representative single lung lobe
from an Elk/0 animal treatedwith bleomycin (n	 4mice).D, lung collagenwas stained usingMasson trichrome. Nikon NIS Elements was utilized to image an
entire lung lobe from an Elk1/0 animal to demonstrate the deposition of collagen across the lobe. Shown is a representative single lung lobe from an Elk1/0
animal treatedwith bleomycin (n	 4mice). E, histological sections of lung from Elk1/0 and Elk1/0 animals following a bleomycinmodel of lung fibrosis were
stained with Masson trichrome and for v6 and pSmad2 by immunohistochemistry. All images were acquired using Nikon NIS Elements and are represen-
tative of a minimum of three (maximum of five) animals. Scale bar	 100 m. i, saline-treated Elk1/0 animal stained with Masson trichrome. ii, saline-treated
Elk1/0 animal stained with Masson trichrome. iii, bleomycin-treated Elk1/0 animal stained with Masson trichrome. iv, bleomycin-treated Elk1/0 animal
stained with Masson trichrome. v, bleomycin-treated Elk1/0 animal immunostained for v6. vi, bleomycin-treated Elk1/0 animal immunostained for
pSmad2. vii, bleomycin-treated Elk1/0 animal immunostained for v6. viii, bleomycin-treated Elk1/0 animal immunostained for pSmad2. F, histological
sections of lung from Elk1/0 and Elk1/0 animals following a bleomycinmodel of lung fibrosis were stained immunohistochemically for pSmad2 (see E, vi and
viii). pSmad2-positive nuclei were quantified. Data are expressed asmean brown nuclei per field of view in bleomycin-treated Elk1/0 (n	 4) and Elk1/0 (n	
5) animals.G, animalswere instilledwith either bleomycinor saline (Sal) and treatedwith either PBSor dexamethasonedaily. Itgb6mRNA levelsweremeasured
in lung homogenates by QPCR after 14 days and were significantly elevated in bleomycin-instilled, PBS-treated mice (n 	 12 mice) compared with saline-
instilled, PBS-treated mice (n	 7 mice). *, p 0.05.
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act as an transcriptional activator, may be important in repair
processes and is the focus of current studies.
Other putative repressors of the ITGB6 promoter high-
lighted by in silico analysis included the progesterone receptor
and GR. Both the progesterone receptor and GR are expressed
in the normal lung (28, 29), and, although the effects of proges-
terone on ITGB6 expression have not been investigated previ-
ously either in the lung or in other tissues, it has been shown to
modulate the expression of several other integrin subunits,
including the 2 and 11 subunits, as well as 11 and v3
integrins in the placenta and endometrium (30, 31). However,
we found no convincing effect of progesterone on basal ITGB6
promoter activity, ITGB6 mRNA levels, or cell surface v6
integrin levels, suggesting that the progesterone receptor is not
a major contributor to repression of ITGB6 in lung epithelial
cells.
In contrast with progesterone, dexamethasone was able to
inhibit TGF1-induced ITGB6 promoter activity and basal
v6 integrin cell surface expression and showed a trend
toward reducing TGF-induced v6 expression in vitro. Fur-
thermore, confirming our in vitro data, activation of GR in vivo
using daily treatment with dexamethasone led to reduced
expression of Itgb6 mRNA in the lung. Although it is possible
that the inhibition of v6 integrin expression is a direct result
of GR activation with consequent binding to, and repression of,
the ITGB6 promoter, we do not favor this hypothesis. Our data
suggest that dexamethasone does not affect basal promoter
activity but, rather, inhibits TGF-1-induced ITGB6 expres-
sion. Furthermore, it has previously been shown that GR can
interrupt TGF/Smad3-mediated plasminogen activator
inhibitor 1 (PAI1) expression via a physical interaction with the
transcriptional activation functions of Smad3 (32). Because
TGF- has been postulated as a positive regulator of v6
integrins via an autocrine loop (17), we hypothesize that GR
reduces v6 protein expression via interrupting this TGF--
mediated autocrine loop.
The effect of siRNA-induced knockdown of Elk1 on both
ITGB6 promoter activity and v6 integrin expression was rel-
atively modest, and the effect of Elk1 siRNA does not com-
pletely recapitulate the effect of loss of the entire repressor
region from the ITGB6 promoter. Efficiency of the siRNA
transfection is unlikely to have reached 100%, which is sup-
ported by the observation that transfectionwith Elk1 siRNAdid
not result in 100% knockdown of Elk1 protein or mRNA. Fur-
thermore, the process of transfecting cells in vitro can often
result in cell injury (33, 34), and it is well documented that
epithelial cell injury results in up-regulation of v6 (8, 12),
which raises the possibility that transfection of the control
siRNAmight have increased v6 expression, therefore reduc-
ing the effect “window” observed when comparing Elk1 siRNA
with control siRNA.Unfortunately, the nuclear location of Elk1
made alternative methods of inhibiting Elk1 difficult.
Importantly, the repressor region of the ITGB6 promoter
contains multiple transcription factor binding sites, many of
which may also exhibit repressor functions on the ITGB6 gene.
In addition to Elk1, our data highlight a potential role for GR in
suppressing v6 expression in vitro and Itgb6 in vivo. How-
ever, inhibiting the actions of Elk1 and GR simultaneously did
not have co-regulatory effects on v6 expression over and
above inhibiting either transcription factor singularly. It is,
therefore, very likely that other factors that may bind the
repressor region are involved in the basal repression of the
ITGB6 gene, some ofwhichmay have combined additive effects
on v6 repression. However, it is beyond the scope of this
manuscript to investigate them all. Fundamentally, a consistent
effect of manipulating Elk1 on ITGB6 promoter, gene, and pro-
tein expression was observed both in vitro and in vivo, high-
lighting a novel and important function for Elk1 in ITGB6
regulation.
These data are the first description of aberrant Elk1 expres-
sion in any fibrotic condition and could help explain the mech-
anisms driving enhanced v6 expression in IPF. Elk1 is an
X-linked gene. Thus, defects in a single allele will have greater
effects in males, which may potentially explain the gender dif-
ferences associated with IPF (35). Levels of Elk1 protein were
reduced in lung tissue homogenates and histological sections
from PF patients, and, furthermore, tissue ChIP analysis
revealed that Elk1 binding to the ITGB6 promoter was reduced
in PF tissue. Expression of ITGB6 is restricted to the epithelium;
therefore, these data suggest that a defect in total lung Elk1 is
likely to play a role in the derepression of epithelial v6 integ-
rin expression observed in fibrotic lung tissue. Although the
mechanisms regulating decreased Elk1 expression in pulmo-
nary fibrosis are unclear, Elk1 is a target of mir-185, which is
increased in lung tissue from patients suffering from rapidly
progressive IPF (36).
Although the focus of this manuscript is on the effect of Elk1
on expression of epithelial restrictedv6 integrins, it is appar-
ent that global loss of Elk1 expression in IPF could have impli-
cations for multiple pathways in many other cells types
involved in the pathogenesis of IPF. Elk1 signaling has been
implicated in regulating elastin expression in lung fibroblasts
(37), hyaluronan expression in dermal fibroblasts (38), and
-smoothmuscle actin in vascular smoothmuscle cells (39), all
of which could have implications for fibrogenesis. Our own in
silico analysis has highlighted the presence of Elk1 binding
FIGURE 6. Expression of Elk1 is reduced in pulmonary fibrosis. A, relative expression of ITGB6mRNA in NF (n	 6 donors) and PF (n	 6 donors) human lung
tissue was assessed by QPCR. Data are expressed as relative mRNA expression compared with NF samples. The line demonstrates the median. *, p 0.05. B,
binding of Elk1 to the ITGB6 promoter in NF and PF tissue as measured by ChIP. Data are expressed as relative binding to the ITGB6 promoter compared with
the IgG control, and themedian is expressed. Relative binding of 1 or below demonstrates no binding to the promoter above IgG. C, densitometry analysis of
Elk1 expression inwhole-lung extracts fromNF (n	 8 donors) and PF (n	 14 donors) donors. Data are expressed as a ratio of Elk1 band intensity:GAPDHband
intensity. **, p 0.01.D, representative immunoblot showing Elk1 and GAPDH expression in NF (n	 4 donors) and PF (n	 5 donors) lung tissue. The ratio of
Elk1:GAPDHas calculatedbydensitometry is shownbeneath thebands. E, immunoblot showingElk1andGAPDHproteinexpression inElk1/0 (n	2mice) and
Elk1/0 (n	 2mice) animals. The ratio of Elk1:GAPDH as calculated by densitometry is shown beneath the bands. F, histological sections of lung from control
(n	4donors) andPF (n	4donors) donorswere immunostained forv6andElk1. All imageswere acquiredusingNikonNIS Elements andare representative
of the donor samples used. Scale bar	 100 m. i, lung tissue from a control donor was stained for v6. ii, lung tissue from a PF donor was stained for v6.
iii, lung tissue from a control donor was stained for Elk1. iv, lung tissue from a PF donor was stained for Elk1.
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motifs in the promoters of several fibrotic genes, including
-smooth muscle actin, the 8 integrin subunit, and TGFRII,
among others. Loss of Elk1 may also affect the expression of
other integrins, such as the v1 integrin, which has recently
been implicated in fibrogenesis in multiple organs (40).
We propose a novel function for the transcription factor Elk1
in fibrosis. Following epithelial cell injury, Elk1 serves to limit
the repair response through repression of ITGB6 transcription
and, therefore, v6 integrins.Where there is failure of repres-
sion through, in part, loss/interruption of Elk1 expression/sig-
naling, fibrogenesis may ensue through enhanced and sus-
tained expression of ITGB6. In summary, this study describes a
novel function for the transcription factor Elk1 in contributing
to repression of v6 integrins in the pulmonary epithelium
and show that reduced Elk1-mediated repression is important
in driving the increased v6 integrin expression and collagen
deposition observed in pulmonary fibrosis.
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